Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.
Mark Cuban's Cost Plus Drug Co. has expanded its offerings to include brand-name medications from J&J subsidiary Janssen. The online wholesaler now sells three Janssen products, Invokana, Invokamet, and Invokamet XR, at significantly reduced prices compared to market rates.
Invokana, a highly effective medication for Type 2 diabetes, typically comes with a hefty price tag of over $675, as stated on Cost Plus Drugs' website. However, with Cuban's enterprise entering the scene, one can now access this vital treatment for a significantly reduced cost of just $243.90.
"This arrangement with Mark Cuban Cost Plus Drug Company is another example of how we [at Janssen] are supporting patient access to needed medicines especially for cash paying patients who are uninsured, or who are underinsured because of cost-shifting by commercial payers." a Janssen spokesperson stated in an emailed statement to The Street. "We have long-standing, strong relationships with all stakeholders across the healthcare system, including with PBMs, that are integral to our efforts to help us maintain market access for our products.”
Reference: Mark Cuban Has Good News for People with Diabetes | April 9, 2023 | Luc Olinga, TheStreet
Reference: Cuban's pharmacy picks up J&J brand-name drugs | April 4, 2023 | Becker's Hospital Review
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.